Supernus Pharma

SUPN NASDAQ
33.75
-0.12
-0.35%
After Hours: 33.75 0 0.00% 16:51 05/22 EDT
Open
33.80
Prev Close
33.87
High
33.97
Low
33.26
Volume
276.93K
Avg Vol (3M)
608.06K
52 Week High
61.25
52 Week Low
30.05
% Turnover
0.53%
Market Cap
1.77B
1D
5D
1M
3M
1Y
5Y

Comments

No Data

Company Profile

Supernus Pharmaceuticals, Inc. is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company offers Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate), its two treatments for patients with epilepsy. In addition, it is developing multiple product candidates in psychiatry to address unmet medical needs and market opportunities for the treatment of impulsive aggression (IA) and for the treatment of attention deficit hyperactivity disorder (ADHD). It is developing SPN-810 (molindone hydrochloride) to treat IA in patients having ADHD. It is developing SPN-812 (viloxazine hydrochloride) as a candidate to treat patients having ADHD. The Company's neurology portfolio consists of Oxtellar XR and Trokendi XR, which are the first once-daily extended release oxcarbazepine and topiramate products, respectively, indicated for epilepsy in the United States market.
MORE >

Recently

Name
Price
%Change